Alisertib (MLN8237) or Investigator&Apos;s Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Millennium Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01482962
First received: November 28, 2011
Last updated: October 15, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2017
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)